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Abstract
Background: Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that predominantly affects the 
optic nerves and the spinal cord, and is possibly mediated by an immune mechanism distinct from that of multiple 
sclerosis (MS). Central scotoma is recognized as a characteristic visual field defect pattern of optic neuritis (ON), 
however, the differing pathogenic mechanisms of NMO and MS may result in different patterns of visual field defects 
for ON.
Methods: Medical records of 15 patients with NMO and 20 patients with MS having ON were retrospectively analyzed. 
A thorough systemic and neurological examination was performed for evaluating ON. The total number of relapses of 
ON and visual fields was investigated. Visual fields were obtained by Goldmann perimeter with each ON relapse.
Results: All MS patients experienced central scotoma, with 90% of them showing central scotoma with every ON 
relapse. However, 53% of NMO patients showed central scotoma with every ON relapse (p = 0.022), and the remaining 
47% of patients experienced non-central scotoma (altitudinal, quadrant, three quadrant, hemianopia, and bitemporal 
hemianopia). Thirteen percent of NMO patients did not experience central scotoma during their disease course. 
Altitudinal hemianopia was the most frequent non-central scotoma pattern in NMO.
Conclusions: NMO patients showed higher incidence of non-central scotoma than MS, and altitudinal hemianopia 
may be characteristic of ON occurring in NMO. As altitudinal hemianopia is highly characteristic of ischemic optic 
neuropathy, we suggest that an ischemic mechanism mediated by anti-aquaporin-4 antibody may play a role in ON in 
NMO patients.
Background
Neuromyelitis optica (NMO; Devic's disease) is an idio-
pathic inflammatory disease of the central nervous sys-
tem (CNS) that mainly affects the optic nerve and spinal
cord. Traditionally, NMO is believed to differ from multi-
ple sclerosis (MS) by causing very severe, often bilateral,
optic neuritis (ON) and longitudinally extensive MRI spi-
nal cord lesions but no MRI brain lesions or aggressive
progression to disability and death [1]. Recent studies
have reported a high frequency of brain MRI abnormali-
ties in NMO patients. However, most were nonspecific
and were not considered typical of MS, and hypothalamic
involvement has been emphasized [2]. NMO has a more
negative outcome than MS, with frequent and early
relapses. Within 5 years of onset, 50% of patients have
become blind in both eyes and cannot walk unassisted,
and 20% die of respiratory failure due to cervical myelitis
[3]. Although no controlled therapeutic trials have been
specifically performed in NMO, case series and observa-
tional studies suggest that azathioprine in combination
with oral steroid reduces the frequency of attacks [4,5],
and rituximab and plasmapheresis can induce clinical
remission of NMO [6-8]. Immuno-suppression rather
than interferon β is the preferred treatment. Thus, distin-
guishing NMO from MS is very important for the thera-
peutic strategy of these disorders. Recently, clinical,
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neuroimaging, laboratory, and pathological features have
been established showing that NMO is distinct from MS.
Histopathological and serological findings strongly sug-
gest the involvement of the humoral immune system [9].
In particular, detection of serum anti-aquaporin-4
(AQP4) antibody can be used to distinguish NMO from
MS [10,11]
ON is the most common and often initial symptom in
both NMO and MS. In acute ON, the cardinal field defect
is a widespread depression of sensitivity, and visual field
testing typically reveals a central scotoma, although other
visual field changes such as color blindness, bitemporal
hemianopia, paracentral scotoma, and altitudinal deficits
have also been reported. ON in NMO tends to be more
severe and recovery is less complete compared with
attacks of ON in the context of MS [3]. Clinical features
such as ocular pain, visual field deficits, and positive phe-
nomena, i.e. movement-induced phosphenes, have been
thought not to differ from those found in MS-associated
attacks [3]. Unlike patients with MS, those with NMO
experience more severe disease symptoms due to myelitis
characterized by centrally located spinal cord lesions that
are longer than three vertebral segments and frequent
early attacks. In NMO, the pathophysiology of spinal cord
lesions and relation with seropositivity for anti-AQP4
antibody are well investigated [12,13]. However, the dif-
ference of clinical symptoms or pathophysiologic findings
for ON between NMO and MS have rarely been evalu-
ated. We hypothesized that the differing pathogenic
mechanisms of NMO and MS may result in different pat-
terns of visual field defects as findings of ON. In this
study, we evaluated the features of visual field defects in
patients with NMO.
Method
We retrospectively analyzed the medical records of 15
patients with NMO (all women, mean age of onset: 36 ±
11, mean ± SD) and 20 patients with MS (5 men and 15
women, 29 ± 9), all of whom had ON. NMO patients ful-
filled Wingerchuk's revised diagnostic criteria [14],
except for NMO-IgG seropositive status. MS patients
included in this study had definitive MS according to
McDonald's criteria [15]. A thorough systemic and neu-
rological examination was performed to evaluate ON.
Visual field tests were performed on the Goldmann
perimeter whenever visual acuity permitted. MRI was
performed where deemed necessary and for those who
could afford the investigation. This study received institu-
tional review board approval and informed consent was
obtained according to the Declaration of Helsinki.
Serum samples were stored at - 80°C until testing for
anti-AQP4 antibody. Anti-AQP4 antibody was assessed
as described previously [12,16]. Briefly, human embry-
onic kidney cells (HEK-293) were stably transfected with
either a vector containing AQP4-cDNA or empty vector,
and specimens were tested by indirect immunofluores-
cence using these two cell lines (with or without AQP4).
Specimens were incubated with the cells for 1 h, washed
in phosphate-buffered saline (PBS), incubated with Alexa
Fluor 488 goat anti-human IgG (Invitrogen, Eugene, Ore-
gon, USA) for 30 min, and washed in PBS. The cells were
then fixed in 4% paraformaldehyde and mounted in Per-
mafluor aqueous mounting media (Beckman Coulter,
Marseille, France).
Statistics
All data in this study are presented as mean ± SD. Cate-
gorical variables were compared using the Mann-Whit-
ney's U test and the Fisher's exact probability test.
Significance levels were set at P < 0.05.
Results
A total of 35 patients were included in this study: 15
NMO and 20 MS (Table 1). There were no differences
between the 2 groups in gender and disease duration.
Patients with NMO were older at disease onset, exhibited
an increased number of total and ON relapses, and had a
higher expanded disability status scale (EDSS) score.
When comparing visual field defect patterns of ON
between the 2 groups, central scotoma was present in 31
out of 33 ON episodes in MS (94%) and 39 out of 51 epi-
sodes in NMO (76%) (p = 0.041, Table 2). In 51 episodes
of ON, NMO patients exhibited 12 episodes of non-cen-
tral scotoma (24%). Of the visual field defect patterns
other than central scotoma, NMO patients showed 5 for
altitudinal, 3 for quadrant, 2 for three quadrant, 1 for
hemianopia, and 1 for bitemporal hemianopia. MS
patients showed 1 each for three quadrant and hemiano-
pia (Table 2).
During the course of the disease, 90% of MS patients
(18/20) showed central scotoma with every episode; how-
ever, central scotoma with every episode was present in
54% of NMO patients (8/15) (p = 0.022, Figure 1). In the
remaining 7 NMO patients, 5 showed both central and
non-central scotoma, and 2 patients showed non-central
scotoma with every episode. In 7 NMO patients showing
non-central scotoma, altitudinal hemianopia was most
frequent (5/7), and the location of the altitudinal hemi-
anopia was inferior in 3 of 5 relapses and superior in 2
relapses. Notably, all altitudinal hemianopia occurred at
the initial attack of each eye (Table 3).
Discussion
A variety of visual field defects may be seen in optic neu-
ropathies, including central, centrocecal, arcuate, altitu-
dinal, and nasal step field defects. Central scotoma isNakajima et al. BMC Neurology 2010, 10:45
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recognized as a typical visual field defect pattern of ON in
MS [17]. In this study, all MS patients experienced central
scotoma, with 90% showing central scotoma with every
ON attack. On the contrary, 53% of NMO patients
showed central scotoma with every ON attack, and the
remaining 47% of patients experienced non-central sco-
toma. Moreover, 13% of NMO patients did not experi-
ence central scotoma during the course of their disease.
Of the non-central scotoma patterns, altitudinal hemi-
anopia was most frequent. Since altitudinal hemianopia
was not recognized in MS patients, this visual field defect
may be characteristic of ON for patients with NMO.
ON is the initial manifestation of NMO in 77% of
patients. In 30% of NMO patients, the initial attack of ON
led to blindness, with only 43% of patients completely
recovering from the first attack. Compared with MS
patients, NMO patients had a significantly higher rate of
bilateral ON (70% versus 19%) [18]. Although the optic
nerve is mainly affected in both NMO and MS, the patho-
genesis of ON in NMO might differ from that of MS.
Compared to MS, the study using optical coherence
tomography indicated a thinner overall average retinal
nerve fiber layer, suggesting widespread axonal injury in
the affected optic nerves in NMO [19].
Pathologically, NMO shares with MS a pattern of focal
demyelination, inflammation, scar formation, and axonal
destruction, but NMO also has an intense perivascular
response, prominent necrosis, and cavitation, which are
not seen in MS [9]. IgG, IgM, and products of comple-
ment activation are deposited in a perivascular pattern in
NMO, suggesting a pathogenic role involving autoanti-
bodies [9]. Blood vessels within demyelination spinal
lesions of NMO are thickened and hyalinized [20]. Active
lesions exhibit tissue swelling, infiltrating polymorpho-
nuclear macrophages, active microglia, demyelination,
axonal loss, prominent necrosis, and variable degrees of
Table 1: Demography and ocular findings of NMO and MS patients
NMO MS P
(n = 15) (n = 20) value
Sex (male/female) 0/15 5/15 0.057
Age at onset 36.0 ± 10.9 29.2 ± 8.8 0.038
Duration of disease (years) 14.4 ± 8.8 11.5 ± 9.9 0.216
Number of total relapses 10.1 ± 4.8 6.3 ± 6.4 0.007
Number of ON relapses 3.4 ± 3.2 1.7 ± 0.8 0.004
EDSS score 5.1 ± 2.5 2.6 ± 1.6 0.009
Brain lesion, % (n) 60 (9) 90 (18) 0.051
Spinal lesion, % (n) 100 (15) 60 (12) 0.005
LESCL, % (n) 87 (13) 10 (2) <0.001
Anti-AQP4 antibody, % (n) 100 (15 ) 0 <0.001
NMO = neuromyelitis optica; MS = multiple sclerosis; ON = optic neuritis; EDSS = expanded disability status scale; LESCL = longitudinally 
extensive spinal cord lesions.
Table 2: Visual field defect patterns of NMO and MS patients
NMO MS P value
Total number of ON relapses 51 33
Visual field defects
Central scotoma (%) 39 (76) 31 (94) 0.041
Non-central scotoma
Altitudinal (%) 5 (10) 0 (0) 0.151
Quadrant (%) 3 (6) 0 (0) 0.276
Three quadrant (%) 2 (4) 1 (3) 1
Hemianopia (%) 1 (2) 1 (3) 1
Bitemporal hemianopia (%) 1 (2) 0 (0) 1
NMO = neuromyelitis optica; MS = multiple sclerosis; ON = optic neuritis.Nakajima et al. BMC Neurology 2010, 10:45
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perivascular inflammation with prominent eosinophils
and products of their exocytosis. Chronic lesions show
gliosis, cystic degeneration, cavitation, and atrophy [21].
These findings suggest that a humoral effector mecha-
nism is initiated by binding of the NMO antibody at the
blood-brain barrier (BBB).
Several studies have reported that areas of CNS inflam-
m a t i o n  c o r r e l a t e  w i t h  e x p r e s s i o n  p a t t e r n  o f  A Q P 4  i n
NMO [22,23]. Expression of AQP4 in the brain and spinal
cord is associated with astrocyte membranes that appose
endothelial cell basal membranes. Astrocytes interact
extensively with endothelial cells to maintain the CNS
BBB, which normally limits the access of immune system
effectors unless localized or distant events disrupt the
BBB, thus allowing access of cellular or soluble immune
effectors. AQP4 is also expressed by astrocytes that sur-
round the optic nerve [24]. Since the optic nerve head is
an area of the CNS where the BBB is more permissive, as
evidenced by immunostaining for markers of intact BBB
[25,26], tissues of the optic nerve might be more sensitive
to AQP4 dysfunction mediated by anti-AQP4 antibodies
[27]. Thus, in NMO, optic nerve lesions would have
demyelination, axonal loss, and perivascular response, as
seen in spinal cord lesions.
Central scotoma is recognized to be a typical visual
field defect pattern of ON in MS. In this study , NMO
patients showed higher incidence of non-central scotoma
than MS patients (p = 0.022, Figure 1); altitudinal hemi-
anopia was more common in non-central scotoma. An
altitudinal visual field defect is suggestive of ischemic
optic neuropathy, which occasionally is the result of pos-
terior ciliary artery occlusion [28,29]. We suggest that
ischemic mechanism mediated by anti-AQP4 antibody
may play a role in ON for NMO patients. Pathological
study demonstrated that vascular degeneration, such as
thickened or hyalinized vessels, existed in the spinal cord
lesions [21]. Recent study indicated that NMO patients
showed more vascular changes, including attenuation of
the peripapillary vascular tree and focal arteriolar nar-
rowing as the retinal features of ON than MS patients
[30]. These vascular changes may results from direct vas-
cular inflammation mediated by anti-AQP4 antibody
[30,31]. Therefore, the tissue organization of optic nerve
cells, such as the vascular structures associated with the
optic nerves, is thought to express AQP4, resulting in
non-central scotoma, especially altitudinal hemianopia.
Although NMO is often fulminant and has a more neg-
ative outcome than MS [32], NMO responds to glucocor-
ticoids, immunosuppressive agents, or plasmapheresis.
Since monosymptomatic ON is often seen as being the
first indication of an attack of NMO and MS, ophthalmo-
scopic examination, especially the visual field test, is
helpful for diagnosis of NMO, and anti-AQP4 antibody
should be checked to decide the most effective treatment
[33].
Conclusion
NMO patients showed higher incidence of non-central
scotoma than MS, and altitudinal hemianopia may be
characteristic of ON occurring in NMO. As altitudinal
hemianopia is highly characteristic of ischemic optic neu-
ropathy, we suggest that an ischemic mechanism medi-
ated by anti-aquaporin-4 antibody may play a role in ON
in NMO patients.
Figure 1 Comparison of visual field defects during the disorders. Ninety percent of MS patients showed central scotoma every time, but 54% in 
NMO (p = 0.022). In NMO patients, 33% of patients showed both central scotoma and non-central scotoma, and 13% of patients showed non-central 
scotoma every time. MS = multiple sclerosis; NMO = neuromyelitis optica.
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Table 3: Clinical findings of 7 NMO patients with non-central scotoma
Patient No. 1 2 3 4 5 6 7
Sex/Age at onset F/48 F/21 F/47 F/34 F/32 F/32 F/54
Duration of disease (years) 9 11 24 4 15 18 12
EDSS score 2.5 1 7 3.5 7 7.5 4
Number of total relapses 5 5 12 6 11 18 23
Number of ON relapses 3 2 2 2 3 4 12
Ocular pain moderate none none mild mild none moderate
Optic disk in acute phase normal NE NE normal normal normal normal
Course of ON lt-altitudinal lt-three quadrant rt-altitudinal lt-altitudinal rt-altitudinal bil-central rt-central
(inferior) rt-altitudinal (superior) (inferior) (superior) lt-guadrant lt-central: 2nd-3rd
rt-central (inferior) rt-central rt-quadrant lt-central rt-hemianopia rt-quadrant
lt-central lt-central lt-three quadrant
rt-central
lt-central
rt-central: 8th-11th
bitemporal
Outcome of ON rt-recover rt-recover rt-recover rt-recover rt-light perception rt-recover rt-light perception
lt-recover lt-recover lt-recover lt-light perception lt-recover lt-light perception
NMO = neuromyelitis optica; EDSS = expanded disability status scale; ON = optic neuritis; NE = not evaluated.Nakajima et al. BMC Neurology 2010, 10:45
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